Immunai
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Last updated on
About Immunai
Founded
2019Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$295MCategory
Sector
Information TechnologyIndustry Group
Software & ServicesIndustry
SoftwareSIC Code
73NAICs Code
51Location
City
New YorkState
New YorkCountry
United StatesTech Stack (68)
